Your browser doesn't support javascript.
loading
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.
Eadie, Laura N; Lagonik, Elias; Page, Elyse C; Schutz, Caitlin E; Heatley, Susan L; McClure, Barbara J; Forgione, Michelle Olivia; Yeung, David T; Hughes, Timothy P; White, Deborah L.
Afiliação
  • Eadie LN; South Australian Health and Medical Research Institute, Adelaide, Australia.
  • Lagonik E; South Australian Health and Medical Research Institute, Adelaide, Australia.
  • Page EC; South Australian Health and Medical Research Institute, Adelaide, Australia.
  • Schutz CE; South Australian Health and Medical Research Institute, Adelaide, Australia.
  • Heatley SL; South Australian Health & Medical Research Institute, Adelaide, Australia.
  • McClure BJ; The University of Adelaide, Australia.
  • Forgione MO; South Australian Health and Medical Research Institute, Adelaide, Australia.
  • Yeung DT; South Australian Health and Medical Research Institute, Adelaide, Australia.
  • Hughes TP; South Australian Health and Medical Research Institute, Adelaide, Australia.
  • White DL; SAHMRI, Adelaide, Australia.
Blood ; 2024 Jun 07.
Article em En | MEDLINE | ID: mdl-38848536
ABSTRACT
High-risk Ph-like ALL includes genomic rearrangement of the ABL1 and ABL2 genes (collectively ABL-rearranged, ABLr), and novel treatments are required. For the first time, we demonstrate asciminib efficacy in ABLr ALL, but only when the ABL SH3 domain is present.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article